Canagliflozin (SGLT2 inhibitor)

metabolic glycemic

Approved medicine for another condition in 6 of 9 markets tracked; in clinical trials in 3.

Evidence so far is from animal studies.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (8)

T3 Miller 2020 Canagliflozin extends life span in genetically heterogeneous male but not female mice doi:10.1172/jci.insight.140019
T3 Snyder 2025 End-of-life pathology in UM-HET3 mice treated with 16 α‑hydroxyestradiol or late‑start canagliflozin doi:10.1007/s11357-025-01741-3
T3 Wang 2025 Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6/HIF-1α signaling doi:10.1080/0886022x.2025.2546624
T3 Jayarathne 2022 Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice doi:10.1111/acel.13653
T3 Jayarathne 2025 Canagliflozin Reprograms the Aging Hippocampus in Genetically Diverse UM ‐ HET 3 Mice and Attenuates Alzheimer's‐Like Pathology doi:10.1111/acel.70255
T3 Jayarathne 2024 Hypothalamic Sex-Specific Metabolic Shift by Canagliflozin during Aging doi:10.1101/2024.03.21.586115
TX Wezeman 2022 Sex Matters in Aging. The Canagliflozin Story doi:10.31491/APT.2022.09.091
TX Jayarathne 2023 Repurposing Canagliflozin to target brain aging doi:10.18632/aging.204624